- Home
- TVGN vs IOBT Comparison
TVGN vs IOBT Comparison
Compare TVGN & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- IOBT
- Stock Information
- Founded
- TVGN 2020
- IOBT 2014
- Country
- TVGN United States
- IOBT Denmark
- Employees
- TVGN N/A
- IOBT 68
- Industry
- TVGN Blank Checks
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- IOBT Health Care
- Exchange
- TVGN Nasdaq
- IOBT Nasdaq
- Market Cap
- TVGN 53.6M
- IOBT 49.4M
- IPO Year
- TVGN N/A
- IOBT 2021
- Fundamental
- Price
- TVGN $1.64
- IOBT $0.68
- Analyst Decision
- TVGN
- IOBT Strong Buy
- Analyst Count
- TVGN 0
- IOBT 3
- Target Price
- TVGN N/A
- IOBT $9.33
- AVG Volume (30 Days)
- TVGN 6.3M
- IOBT 409.4K
- Earning Date
- TVGN 11-29-2024
- IOBT 11-12-2024
- Dividend Yield
- TVGN N/A
- IOBT N/A
- EPS Growth
- TVGN N/A
- IOBT N/A
- EPS
- TVGN N/A
- IOBT N/A
- Revenue
- TVGN N/A
- IOBT N/A
- Revenue This Year
- TVGN N/A
- IOBT N/A
- Revenue Next Year
- TVGN N/A
- IOBT N/A
- P/E Ratio
- TVGN N/A
- IOBT N/A
- Revenue Growth
- TVGN N/A
- IOBT N/A
- 52 Week Low
- TVGN $0.26
- IOBT $0.69
- 52 Week High
- TVGN $21.09
- IOBT $2.10
- Technical
- Relative Strength Index (RSI)
- TVGN 52.11
- IOBT 27.19
- Support Level
- TVGN $1.26
- IOBT $0.79
- Resistance Level
- TVGN $1.76
- IOBT $0.98
- Average True Range (ATR)
- TVGN 0.33
- IOBT 0.13
- MACD
- TVGN -0.07
- IOBT -0.04
- Stochastic Oscillator
- TVGN 46.67
- IOBT 3.15
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.